TY - JOUR AU - Swain, S. M. AU - Baselga, J. AU - Kim, S. B. AU - Ro, J. AU - Semiglazov, V. AU - Campone, M. AU - Ciruelos, E. AU - Ferrero, J. M. AU - Schneeweiss, A. AU - Heeson, S. PY - 2015 DA - 2015// TI - Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer JO - N Engl J Med VL - 372 UR - https://doi.org/10.1056/NEJMoa1413513 DO - 10.1056/NEJMoa1413513 ID - Swain2015 ER - TY - JOUR AU - Baselga, J. AU - Cortes, J. AU - Kim, S. B. AU - Im, S. A. AU - Hegg, R. AU - Im, Y. H. AU - Roman, L. AU - Pedrini, J. L. AU - Pienkowski, T. AU - Knott, A. PY - 2012 DA - 2012// TI - Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer JO - N Engl J Med VL - 366 UR - https://doi.org/10.1056/NEJMoa1113216 DO - 10.1056/NEJMoa1113216 ID - Baselga2012 ER - TY - JOUR AU - Amiri-Kordestani, L. AU - Wedam, S. AU - Zhang, L. AU - Tang, S. AU - Tilley, A. AU - Ibrahim, A. AU - Justice, R. AU - Pazdur, R. AU - Cortazar, P. PY - 2014 DA - 2014// TI - First FDA approval of neoadjuvant therapy for breast cancer: pertuzumab for the treatment of patients with HER2-positive breast cancer JO - Clin Cancer Res VL - 20 UR - https://doi.org/10.1158/1078-0432.CCR-14-1268 DO - 10.1158/1078-0432.CCR-14-1268 ID - Amiri-Kordestani2014 ER - TY - JOUR AU - Schneeweiss, A. AU - Chia, S. AU - Hickish, T. AU - Harvey, V. AU - Eniu, A. AU - Hegg, R. AU - Tausch, C. AU - Seo, J. H. AU - Tsai, Y. F. AU - Ratnayake, J. PY - 2013 DA - 2013// TI - Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA) JO - Ann Oncol VL - 24 UR - https://doi.org/10.1093/annonc/mdt182 DO - 10.1093/annonc/mdt182 ID - Schneeweiss2013 ER - TY - JOUR AU - Gianni, L. AU - Pienkowski, T. AU - Im, Y. H. AU - Roman, L. AU - Tseng, L. M. AU - Liu, M. C. AU - Lluch, A. AU - Staroslawska, E. PY - 2012 DA - 2012// TI - de la Haba-Rodriguez J, Im SA et al: Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial JO - Lancet Oncol VL - 13 UR - https://doi.org/10.1016/S1470-2045(11)70336-9 DO - 10.1016/S1470-2045(11)70336-9 ID - Gianni2012 ER - TY - STD TI - von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, Suter T, Arahmani A, Rouchet N, Clark E, et al. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. N Engl J Med. 2017. ID - ref6 ER - TY - JOUR AU - Seidman, A. AU - Hudis, C. AU - Pierri, M. K. AU - Shak, S. AU - Paton, V. AU - Ashby, M. AU - Murphy, M. AU - Stewart, S. J. AU - Keefe, D. PY - 2002 DA - 2002// TI - Cardiac dysfunction in the trastuzumab clinical trials experience JO - J Clin Oncol VL - 20 UR - https://doi.org/10.1200/JCO.2002.20.5.1215 DO - 10.1200/JCO.2002.20.5.1215 ID - Seidman2002 ER - TY - JOUR AU - Slamon, D. J. AU - Leyland-Jones, B. AU - Shak, S. AU - Fuchs, H. AU - Paton, V. AU - Bajamonde, A. AU - Fleming, T. AU - Eiermann, W. AU - Wolter, J. AU - Pegram, M. PY - 2001 DA - 2001// TI - Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 JO - N Engl J Med VL - 344 UR - https://doi.org/10.1056/NEJM200103153441101 DO - 10.1056/NEJM200103153441101 ID - Slamon2001 ER - TY - JOUR AU - Martin, M. AU - Sanchez-Rovira, P. AU - Munoz, M. AU - Baena-Canada, J. M. AU - Mel, J. R. AU - Margeli, M. AU - Ramos, M. AU - Martinez, E. AU - Garcia-Saenz, J. A. AU - Casado, A. PY - 2011 DA - 2011// TI - Pegylated liposomal doxorubicin in combination with cyclophosphamide and trastuzumab in HER2-positive metastatic breast cancer patients: efficacy and cardiac safety from the GEICAM/2004-05 study JO - Ann Oncol VL - 22 UR - https://doi.org/10.1093/annonc/mdr024 DO - 10.1093/annonc/mdr024 ID - Martin2011 ER - TY - JOUR AU - Baselga, J. AU - Manikhas, A. AU - Cortes, J. AU - Llombart, A. AU - Roman, L. AU - Semiglazov, V. F. AU - Byakhov, M. AU - Lokanatha, D. AU - Forenza, S. AU - Goldfarb, R. H. PY - 2014 DA - 2014// TI - Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer JO - Ann Oncol VL - 25 UR - https://doi.org/10.1093/annonc/mdt543 DO - 10.1093/annonc/mdt543 ID - Baselga2014 ER - TY - JOUR AU - Vici, P. AU - Colucci, G. AU - Giotta, F. AU - Sergi, D. AU - Filippelli, G. AU - Perri, P. AU - Botti, C. AU - Vizza, E. AU - Carpino, A. AU - Pizzuti, L. PY - 2011 DA - 2011// TI - A multicenter prospective phase II randomized trial of epirubicin/vinorelbine versus pegylated liposomal doxorubicin/vinorelbine as first-line treatment in advanced breast cancer. A GOIM study JO - J Exp Clin Cancer Res VL - 30 UR - https://doi.org/10.1186/1756-9966-30-39 DO - 10.1186/1756-9966-30-39 ID - Vici2011 ER - TY - JOUR AU - Vici, P. AU - Pizzuti, L. AU - Gamucci, T. AU - Sergi, D. AU - Conti, F. AU - Zampa, G. AU - Medico, P. AU - Vita, R. AU - Pozzi, M. AU - Botti, C. PY - 2014 DA - 2014// TI - Non-pegylated liposomal Doxorubicin-cyclophosphamide in sequential regimens with taxanes as neoadjuvant chemotherapy in breast cancer patients JO - J Cancer VL - 5 UR - https://doi.org/10.7150/jca.9132 DO - 10.7150/jca.9132 ID - Vici2014 ER - TY - JOUR AU - Harris, K. A. AU - Harney, E. AU - Small, E. J. PY - 2002 DA - 2002// TI - Liposomal doxorubicin for the treatment of hormone-refractory prostate cancer JO - Clin Prostate Cancer VL - 1 UR - https://doi.org/10.3816/CGC.2002.n.005 DO - 10.3816/CGC.2002.n.005 ID - Harris2002 ER - TY - JOUR AU - O'Brien, M. E. AU - Wigler, N. AU - Inbar, M. AU - Rosso, R. AU - Grischke, E. AU - Santoro, A. AU - Catane, R. AU - Kieback, D. G. AU - Tomczak, P. AU - Ackland, S. P. PY - 2004 DA - 2004// TI - Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer JO - Ann Oncol VL - 15 UR - https://doi.org/10.1093/annonc/mdh097 DO - 10.1093/annonc/mdh097 ID - O'Brien2004 ER - TY - JOUR AU - Chan, S. AU - Davidson, N. AU - Juozaityte, E. AU - Erdkamp, F. AU - Pluzanska, A. AU - Azarnia, N. AU - Lee, L. W. PY - 2004 DA - 2004// TI - Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer JO - Ann Oncol VL - 15 UR - https://doi.org/10.1093/annonc/mdh393 DO - 10.1093/annonc/mdh393 ID - Chan2004 ER - TY - JOUR AU - Sparano, J. A. AU - Makhson, A. N. AU - Semiglazov, V. F. AU - Tjulandin, S. A. AU - Balashova, O. I. AU - Bondarenko, I. N. AU - Bogdanova, N. V. AU - Manikhas, G. M. AU - Oliynychenko, G. P. AU - Chatikhine, V. A. PY - 2009 DA - 2009// TI - Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracycline therapy: results from a randomized phase III study JO - J Clin Oncol VL - 27 UR - https://doi.org/10.1200/JCO.2008.20.5013 DO - 10.1200/JCO.2008.20.5013 ID - Sparano2009 ER - TY - STD TI - van Dalen EC, Michiels EMC, Caron HN, Kremer LCM: Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev 2010(5). ID - ref17 ER - TY - JOUR AU - Buzdar, A. U. AU - Suman, V. J. AU - Meric-Bernstam, F. AU - Leitch, A. M. AU - Ellis, M. J. AU - Boughey, J. C. AU - Unzeitig, G. AU - Royce, M. AU - McCall, L. M. AU - Ewer, M. S. PY - 2013 DA - 2013// TI - Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial JO - Lancet Oncol VL - 14 UR - https://doi.org/10.1016/S1470-2045(13)70502-3 DO - 10.1016/S1470-2045(13)70502-3 ID - Buzdar2013 ER - TY - JOUR AU - Wolff, A. C. AU - Hammond, M. E. AU - Hicks, D. G. AU - Dowsett, M. AU - McShane, L. M. AU - Allison, K. H. AU - Allred, D. C. AU - Bartlett, J. M. AU - Bilous, M. AU - Fitzgibbons, P. PY - 2013 DA - 2013// TI - Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update JO - J Clin Oncol VL - 31 UR - https://doi.org/10.1200/JCO.2013.50.9984 DO - 10.1200/JCO.2013.50.9984 ID - Wolff2013 ER - TY - JOUR AU - Gavilá, J. AU - Fernández-Abad, M. AU - Pérez, J. AU - Guerrero, Á. AU - Oliveira, M. AU - Llobet-Canela, M. AU - Llombart, A. PY - 2015 DA - 2015// TI - P200 Neoadjuvant therapy in HER2+ breast cancer: Opti-HER Heart run-in phase safety data (SOLTI-1002) JO - Breast VL - 24 UR - https://doi.org/10.1016/S0960-9776(15)70234-1 DO - 10.1016/S0960-9776(15)70234-1 ID - Gavilá2015 ER - TY - JOUR AU - LEVIN, R. AU - DOLGIN, M. AU - FOX, C. AU - GORLIN, R. PY - 1994 DA - 1994// TI - The Criteria Committee of the New York Heart Association: Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels JO - LWW Handbooks VL - 9 ID - LEVIN1994 ER - TY - JOUR AU - Prat, A. AU - Galván, P. AU - Jimenez, B. AU - Buckingham, W. AU - Jeiranian, H. A. AU - Schaper, C. AU - Vidal, M. AU - Álvarez, M. AU - Díaz, S. AU - Ellis, C. PY - 2016 DA - 2016// TI - Prediction of response to neoadjuvant chemotherapy using core needle biopsy samples with the prosigna assay JO - Clin Cancer Res VL - 22 UR - https://doi.org/10.1158/1078-0432.CCR-15-0630 DO - 10.1158/1078-0432.CCR-15-0630 ID - Prat2016 ER - TY - STD TI - Llombart-Cussac A, Cortes J, Pare L, Galvan P, Bermejo B, Martinez N, Vidal M, Pernas S, Lopez R, Munoz M, et al. HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial. Lancet Oncol. 2017. ID - ref23 ER - TY - JOUR AU - Gavila, J. AU - Guerrero, A. AU - Climent, M. A. AU - Fernandez, A. AU - Gozalbo, F. AU - Carrascosa, M. AU - Camps, J. AU - Guillem, V. AU - Ruiz, A. PY - 2015 DA - 2015// TI - Efficacy and safety of neoadjuvant chemotherapy with concurrent liposomal-encapsulated doxorubicin, paclitaxel and trastuzumab for human epidermal growth factor receptor 2-positive breast cancer in clinical practice JO - Int J Clin Oncol VL - 20 UR - https://doi.org/10.1007/s10147-014-0727-x DO - 10.1007/s10147-014-0727-x ID - Gavila2015 ER - TY - JOUR AU - Cortes, J. AU - Cosimo, S. AU - Climent, M. A. AU - Cortes-Funes, H. AU - Lluch, A. AU - Gascon, P. AU - Mayordomo, J. I. AU - Gil, M. AU - Benavides, M. AU - Cirera, L. PY - 2009 DA - 2009// TI - Nonpegylated liposomal doxorubicin (TLC-D99), paclitaxel, and trastuzumab in HER-2-overexpressing breast cancer: a multicenter phase I/II study JO - Clin Cancer Res VL - 15 UR - https://doi.org/10.1158/1078-0432.CCR-08-1113 DO - 10.1158/1078-0432.CCR-08-1113 ID - Cortes2009 ER - TY - JOUR AU - Buzdar, A. U. AU - Ibrahim, N. K. AU - Francis, D. AU - Booser, D. J. AU - Thomas, E. S. AU - Theriault, R. L. AU - Pusztai, L. AU - Green, M. C. AU - Arun, B. K. AU - Giordano, S. H. PY - 2005 DA - 2005// TI - Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer JO - J Clin Oncol VL - 23 UR - https://doi.org/10.1200/JCO.2005.07.032 DO - 10.1200/JCO.2005.07.032 ID - Buzdar2005 ER - TY - JOUR AU - Buzdar, A. U. AU - Valero, V. AU - Ibrahim, N. K. AU - Francis, D. AU - Broglio, K. R. AU - Theriault, R. L. AU - Pusztai, L. AU - Green, M. C. AU - Singletary, S. E. AU - Hunt, K. K. PY - 2007 DA - 2007// TI - Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen JO - Clin Cancer Res VL - 13 UR - https://doi.org/10.1158/1078-0432.CCR-06-1345 DO - 10.1158/1078-0432.CCR-06-1345 ID - Buzdar2007 ER - TY - JOUR AU - Gianni, L. AU - Eiermann, W. AU - Semiglazov, V. AU - Manikhas, A. AU - Lluch, A. AU - Tjulandin, S. AU - Zambetti, M. AU - Vazquez, F. AU - Byakhow, M. AU - Lichinitser, M. PY - 2010 DA - 2010// TI - Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort JO - Lancet VL - 375 UR - https://doi.org/10.1016/S0140-6736(09)61964-4 DO - 10.1016/S0140-6736(09)61964-4 ID - Gianni2010 ER - TY - JOUR AU - Lenihan, D. AU - Suter, T. AU - Brammer, M. AU - Neate, C. AU - Ross, G. AU - Baselga, J. PY - 2012 DA - 2012// TI - Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab JO - Ann Oncol VL - 23 UR - https://doi.org/10.1093/annonc/mdr294 DO - 10.1093/annonc/mdr294 ID - Lenihan2012 ER - TY - JOUR AU - Schneeweiss, A. AU - Chia, S. AU - Hickish, T. AU - Harvey, V. AU - Eniu, A. AU - Waldron-Lynch, M. AU - Eng-Wong, J. AU - Kirk, S. AU - Cortes, J. PY - 2018 DA - 2018// TI - Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer JO - Eur J Cancer VL - 89 UR - https://doi.org/10.1016/j.ejca.2017.10.021 DO - 10.1016/j.ejca.2017.10.021 ID - Schneeweiss2018 ER - TY - JOUR AU - Loibl, S. AU - Jackisch, C. AU - Schneeweiss, A. AU - Schmatloch, S. AU - Aktas, B. AU - Denkert, C. AU - Wiebringhaus, H. AU - Kümmel, S. AU - Warm, M. AU - Paepke, S. PY - 2017 DA - 2017// TI - Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial JO - Ann Oncol VL - 28 ID - Loibl2017 ER - TY - STD TI - Van Ramshorst MS, van Werkhoven E, Mandjes IA, Kemper I, Dezentje VO, Oving IM, Honkoop AH, Tick LW, Van de Wouw AW, Mandigers CM. A phase III trial of neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2-blockade for HER2+ breast cancer: The TRAIN-2 study (BOOG 2012-03). Proc Am Soc Clin Oncol. 2017. ID - ref32 ER - TY - JOUR AU - Foldi, J. AU - Mougalian, S. AU - Silber, A. AU - Lannin, D. AU - Killelea, B. AU - Chagpar, A. AU - Horowitz, N. AU - Frederick, C. AU - Rispoli, L. AU - Burrello, T. PY - 2018 DA - 2018// TI - Single-arm, neoadjuvant, phase II trial of pertuzumab and trastuzumab administered concomitantly with weekly paclitaxel followed by 5-fluoruracil, epirubicin, and cyclophosphamide (FEC) for stage I–III HER2-positive breast cancer JO - Breast Cancer Res Treat VL - 169 UR - https://doi.org/10.1007/s10549-017-4653-2 DO - 10.1007/s10549-017-4653-2 ID - Foldi2018 ER - TY - JOUR AU - Swain, S. AU - Ewer, M. AU - Viale, G. AU - Delaloge, S. AU - Ferrero, J. -. M. AU - Verrill, M. AU - Colomer, R. AU - Vieira, C. AU - Werner, T. AU - Douthwaite, H. PY - 2017 DA - 2017// TI - Pertuzumab, trastuzumab, and standard anthracycline-and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study JO - Ann Oncol VL - 29 UR - https://doi.org/10.1093/annonc/mdx773 DO - 10.1093/annonc/mdx773 ID - Swain2017 ER - TY - STD TI - Hurvitz SA, Martin M, Symmans WF, Jung KH, Huang C-S, Thompson AM, Harbeck N, Valero V, Stroyakovskiy D, Wildiers H. Pathologic complete response (pCR) rates after neoadjuvant trastuzumab emtansine (T-DM1 [K])+ pertuzumab (P) vs docetaxel+ carboplatin+ trastuzumab+ P (TCHP) treatment in patients with HER2-positive (HER2+) early breast cancer (EBC)(KRISTINE). Proc Am Soc Clin Oncol. 2016. ID - ref35 ER - TY - JOUR AU - Baselga, J. AU - Bradbury, I. AU - Eidtmann, H. AU - Cosimo, S. AU - Azambuja, E. AU - Aura, C. AU - Gómez, H. AU - Dinh, P. AU - Fauria, K. AU - Dooren, V. PY - 2012 DA - 2012// TI - Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial JO - The Lancet VL - 379 UR - https://doi.org/10.1016/S0140-6736(11)61847-3 DO - 10.1016/S0140-6736(11)61847-3 ID - Baselga2012 ER - TY - JOUR AU - Guarneri, V. AU - Frassoldati, A. AU - Bottini, A. AU - Cagossi, K. AU - Bisagni, G. AU - Sarti, S. AU - Ravaioli, A. AU - Cavanna, L. AU - Giardina, G. AU - Musolino, A. PY - 2012 DA - 2012// TI - Preoperative Chemotherapy Plus Trastuzumab, Lapatinib, or Both in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: Results of the Randomized Phase II CHER-LOB Study JO - J Clin Oncol VL - 30 UR - https://doi.org/10.1200/JCO.2011.39.0823 DO - 10.1200/JCO.2011.39.0823 ID - Guarneri2012 ER - TY - STD TI - Untch M, Loibl S, Bischoff J, Eidtmann H, Kaufmann M, Blohmer J-U, Hilfrich J, Strumberg D, Fasching PA, Kreienberg R, et al. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol. 13(2):135–44. ID - ref38 ER - TY - STD TI - Robidoux A, Tang G, Rastogi P, Geyer CE Jr, Azar CA, Atkins JN, Fehrenbacher L, Bear HD, Baez-Diaz L, Sarwar S, et al. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial. Lancet Oncol. 14(12):1183–92. ID - ref39 ER - TY - STD TI - von Minckwitz G, Schneeweiss A, Loibl S, Salat C, Denkert C, Rezai M, Blohmer JU, Jackisch C, Paepke S, Gerber B, et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol. 15(7):747–56. ID - ref40 ER - TY - STD TI - Untch M, Fasching PA, Konecny GE, Hasmüller S, Lebeau A, Kreienberg R, Camara O, Müller V, du Bois A, Kühn T et al: Pathologic Complete Response After Neoadjuvant Chemotherapy Plus Trastuzumab Predicts Favorable Survival in Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: Results From the TECHNO Trial of the AGO and GBG Study Groups. J Clin Oncol 2011, 29(25):3351-3357. ID - ref41 ER - TY - JOUR AU - Untch, M. AU - Rezai, M. AU - Loibl, S. AU - Fasching, P. A. AU - Huober, J. AU - Tesch, H. AU - Bauerfeind, I. AU - Hilfrich, J. AU - Eidtmann, H. AU - Gerber, B. PY - 2010 DA - 2010// TI - Neoadjuvant Treatment With Trastuzumab in HER2-Positive Breast Cancer: Results From the GeparQuattro Study JO - J Clin Oncol VL - 28 UR - https://doi.org/10.1200/JCO.2009.23.8451 DO - 10.1200/JCO.2009.23.8451 ID - Untch2010 ER - TY - JOUR AU - Carey, L. A. AU - Berry, D. A. AU - Cirrincione, C. T. AU - Barry, W. T. AU - Pitcher, B. N. AU - Harris, L. N. AU - Ollila, D. W. AU - Krop, I. E. AU - Henry, N. L. AU - Weckstein, D. J. PY - 2016 DA - 2016// TI - Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib JO - J Clin Oncol VL - 34 UR - https://doi.org/10.1200/JCO.2015.62.1268 DO - 10.1200/JCO.2015.62.1268 ID - Carey2016 ER - TY - JOUR AU - Fumagalli, D. AU - Venet, D. AU - Ignatiadis, M. AU - Azim, H. A. AU - Maetens, M. AU - Rothé, F. AU - Salgado, R. AU - Bradbury, I. AU - Pusztai, L. AU - Harbeck, N. PY - 2017 DA - 2017// TI - RNA sequencing to predict response to neoadjuvant anti-HER2 therapy: a secondary analysis of the NeoALTTO randomized clinical trial JO - JAMA Oncol VL - 3 UR - https://doi.org/10.1001/jamaoncol.2016.3824 DO - 10.1001/jamaoncol.2016.3824 ID - Fumagalli2017 ER - TY - CHAP AU - Tolaney, S. M. AU - Barry, W. T. AU - Guo, H. AU - Dillon, D. AU - Dang, C. T. AU - Yardley, D. A. AU - Moy, B. AU - Marcom, P. K. AU - Albain, K. S. AU - Rugo, H. S. PY - 2017 DA - 2017// TI - Seven-year (yr) follow-up of adjuvant paclitaxel (T) and trastuzumab (H)(APT trial) for node-negative, HER2-positive breast cancer (BC) BT - American Society of Clinical Oncology ID - Tolaney2017 ER - TY - STD TI - Veeraraghavan J, De Angelis C, Reis-Filho JS, Pascual T, Prat A, Rimawi MF, Osborne CK, Schiff R. De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance. Breast. 2017. ID - ref46 ER - TY - JOUR AU - Prat, A. AU - Perou, C. M. PY - 2011 DA - 2011// TI - Deconstructing the molecular portraits of breast cancer JO - Mol Oncol VL - 5 UR - https://doi.org/10.1016/j.molonc.2010.11.003 DO - 10.1016/j.molonc.2010.11.003 ID - Prat2011 ER - TY - JOUR AU - Prat, A. AU - Bianchini, G. AU - Thomas, M. AU - Belousov, A. AU - Cheang, M. C. AU - Koehler, A. AU - Gomez, P. AU - Semiglazov, V. AU - Eiermann, W. AU - Tjulandin, S. PY - 2014 DA - 2014// TI - Research-based PAM50 subtype predictor identifies higher responses and improved survival outcomes in HER2-positive breast cancer in the NOAH study JO - Clin Cancer Res VL - 20 UR - https://doi.org/10.1158/1078-0432.CCR-13-0239 DO - 10.1158/1078-0432.CCR-13-0239 ID - Prat2014 ER - TY - JOUR AU - Prat, A. AU - Pineda, E. AU - Adamo, B. AU - Galvan, P. AU - Fernandez, A. AU - Gaba, L. AU - Diez, M. AU - Viladot, M. AU - Arance, A. AU - Munoz, M. PY - 2015 DA - 2015// TI - Clinical implications of the intrinsic molecular subtypes of breast cancer JO - Breast VL - 24 UR - https://doi.org/10.1016/j.breast.2015.07.008 DO - 10.1016/j.breast.2015.07.008 ID - Prat2015 ER - TY - STD TI - Prat A, Carey LA, Adamo B, Vidal M, Tabernero J, Cortés J, Parker JS, Perou CM, Baselga J. Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer. JNCI. 2014;106(8). ID - ref50 ER - TY - JOUR AU - Prat, A. AU - Fan, C. AU - Fernandez, A. AU - Hoadley, K. A. AU - Martinello, R. AU - Vidal, M. AU - Viladot, M. AU - Pineda, E. AU - Arance, A. AU - Munoz, M. PY - 2015 DA - 2015// TI - Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy JO - BMC Med VL - 13 UR - https://doi.org/10.1186/s12916-015-0540-z DO - 10.1186/s12916-015-0540-z ID - Prat2015 ER - TY - JOUR AU - Lesurf, R. AU - Griffith, O. L. AU - Griffith, M. AU - Hundal, J. AU - Trani, L. AU - Watson, M. A. AU - Aft, R. AU - Ellis, M. J. AU - Ota, D. AU - Suman, V. J. PY - 2017 DA - 2017// TI - Genomic characterization of HER2-positive breast cancer and response to neoadjuvant trastuzumab and chemotherapy-results from the ACOSOG Z1041 (Alliance) trial JO - Ann Oncol VL - 28 UR - https://doi.org/10.1093/annonc/mdx048 DO - 10.1093/annonc/mdx048 ID - Lesurf2017 ER - TY - JOUR AU - Dieci, M. V. AU - Prat, A. AU - Tagliafico, E. AU - Pare, L. AU - Ficarra, G. AU - Bisagni, G. AU - Piacentini, F. AU - Generali, D. G. AU - Conte, P. AU - Guarneri, V. PY - 2016 DA - 2016// TI - Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial JO - Ann Oncol VL - 27 UR - https://doi.org/10.1093/annonc/mdw262 DO - 10.1093/annonc/mdw262 ID - Dieci2016 ER - TY - JOUR AU - Prat, A. AU - Navarro, A. AU - Pare, L. AU - Reguart, N. AU - Galvan, P. AU - Pascual, T. AU - Martinez, A. AU - Nuciforo, P. AU - Comerma, L. AU - Alos, L. PY - 2017 DA - 2017// TI - Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma JO - Cancer Res VL - 77 UR - https://doi.org/10.1158/0008-5472.CAN-16-3556 DO - 10.1158/0008-5472.CAN-16-3556 ID - Prat2017 ER - TY - JOUR AU - Danaher, P. AU - Warren, S. AU - Dennis, L. AU - D'Amico, L. AU - White, A. AU - Disis, M. L. AU - Geller, M. A. AU - Odunsi, K. AU - Beechem, J. AU - Fling, S. P. PY - 2017 DA - 2017// TI - Gene expression markers of Tumor Infiltrating Leukocytes JO - J Immunother Cancer VL - 5 UR - https://doi.org/10.1186/s40425-017-0215-8 DO - 10.1186/s40425-017-0215-8 ID - Danaher2017 ER -